Host cell invasion in mucormycosis: Role of iron

Current Opinion in Microbiology

Volumn 14, Issue 4, 2011, Pages 406-411

  Ibrahim, Ashraf S ^a,b  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE REGULATED PROTEIN 78; IRON;

CELL ADHESION; CELL INTERACTION; CELL INVASION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HOST CELL; HOST RESISTANCE; HUMAN; IRON BLOOD LEVEL; IRON METABOLISM; MUCORALES; MUCORMYCOSIS; NONHUMAN; PATHOGENESIS; PHAGOCYTE; REVIEW; RHIZOPUS ORYZAE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; CELL ADHESION; EXTRACELLULAR MATRIX PROTEINS; HOST-PATHOGEN INTERACTIONS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNE EVASION; IRON; MICE; MUCORMYCOSIS; PHAGOCYTES; RECEPTORS, NEUROPEPTIDE; RHIZOPUS; SPORES, FUNGAL;

MUCORALES;

EID: 80051799934     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2011.07.004     Document Type: Review

References (57)

1. Ribes J.A., Vanover-Sams C.L., Baker D.J. Zygomycetes in human disease. Clin Microbiol Rev 2000, 13:236-301.
2. Spellberg B., Edwards J., Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005, 18:556-569.
3. Roden M.M., Zaoutis T.E., Buchanan W.L., Knudsen T.A., Sarkisova T.A., Schaufele R.L., Sein M., Sein T., Chiou C.C., Chu J.H., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634-653.
4. Gleissner B., Schilling A., Anagnostopolous I., Siehl I., Thiel E. Improved outcome of zygomycosis in patients with hematological diseases?. Leuk Lymphoma 2004, 45:1351-1360.
5. Marr K.A., Carter R.A., Crippa F., Wald A., Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34:909-917.
6. Kontoyiannis D.P., Wessel V.C., Bodey G.P., Rolston K.V. Zygomycosis in the 1990 in a tertiary-care cancer center. Clin Infect Dis 2000, 30:851-856.
7. Greenberg R.N., Scott L.J., Vaughn H.H., Ribes J.A. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004, 17:517-525.
8. Bitar D., Van Cauteren D., Lanternier F., Dannaoui E., Che D., Dromer F., Desenclos J.C., Lortholary O. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009, 15:1395-1401.
9. Chakrabarti A., Chatterjee S.S., Shivaprakash M.R. Overview of opportunistic fungal infections in India. Nippon Ishinkin Gakkai Zasshi 2008, 49:165-172.
10. Chakrabarti A., Chatterjee S.S., Das A., Panda N., Shivaprakash M.R., Kaur A., Varma S.C., Singhi S., Bhansali A., Sakhuja V. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J 2009, 85:573-581.
11. Kauffman C.A. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 2004, 39:588-590.
12. Siwek G.T., Dodgson K.J., de Magalhaes-Silverman M., Bartelt L.A., Kilborn S.B., Hoth P.L., Diekema D.J., Pfaller M.A. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004, 39:584-587.
13. Sugar A.M. Agents of mucormycosis and related species. Principles and Practice of Infectious Diseases 2005, 2979. Elsevier. edn 6. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
14. Ibrahim A.S., Spellberg B., Edwards J. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 2008, 21:620-625.
15. Artis W.M., Fountain J.A., Delcher H.K., Jones H.E. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982, 31:1109-1114.
16. Timpl R., Rohde H., Robey P.G., Rennard S.I., Foidart J.M., Martin G.R. Laminin - a glycoprotein from basement membranes. J Biol Chem 1979, 254:9933-9937.
17. Bouchara J.P., Oumeziane N.A., Lissitzky J.C., Larcher G., Tronchin G., Chabasse D. Attachment of spores of the human pathogenic fungus Rhizopus oryzae to extracellular matrix components. Eur J Cell Biol 1996, 70:76-83.
18. Ma L.J., Ibrahim A.S., Skory C., Grabherr M.G., Burger G., Butler M., Elias M., Idnurm A., Lang B.F., Sone T., et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet 2009, 5:e1000549.
19. Farley P.C., Sullivan P.A. The Rhizopus oryzae secreted aspartic proteinase gene family: an analysis of gene expression. Microbiology 1998, 144(Pt 8):2355-2366.
20. Chen C.C., Cho Y.C., Lai C.C., Hsu W.H. Purification and characterization of a new Rhizopuspepsin from Rhizopus oryzae NBRC 4749. J Agric Food Chem 2009, 57:6742-6747.
21. M'Hir S., Rizzello C.G., Di Cagno R., Cassone A., Hamdi M. Use of selected enterococci and Rhizopus oryzae proteases to hydrolyse wheat proteins responsible for celiac disease. J Appl Microbiol 2009, 106:421-431.
22. Egusa S., Otani H. Characterization of a cellular immunostimulating peptide from a soybean protein fraction digested with peptidase R. J Nutr Sci Vitaminol (Tokyo) 2009, 55:428-433.
23. Egusa S., Otani H. Soybean protein fraction digested with neutral protease preparation, " Peptidase R" , produced by Rhizopus oryzae, stimulates innate cellular immune system in mouse. Int Immunopharmacol 2009, 9:931-936.
24. Sanglard D., Hube B., Monod M., Odds F.C., Gow N.A. A triple deletion of the secreted aspartyl proteinase genes SAP4, SAP5, and SAP6 of Candida albicans causes attenuated virulence. Infect Immun 1997, 65:3539-3546.
25. Hube B., Sanglard D., Odds F.C., Hess D., Monod M., Schafer W., Brown A.J., Gow N.A. Disruption of each of the secreted aspartyl proteinase genes SAP1, SAP2, and SAP3 of Candida albicans attenuates virulence. Infect Immun 1997, 65:3529-3538.
26. Schoen C., Reichard U., Monod M., Kratzin H.D., Ruchel R. Molecular cloning of an extracellular aspartic proteinase from Rhizopus microsporus and evidence for its expression during infection. Med Mycol 2002, 40:61-71.
27. Spreer A., Ruchel R., Reichard U. Characterization of an extracellular subtilisin protease of Rhizopus microsporus and evidence for its expression during invasive rhinoorbital mycosis. Med Mycol 2006, 44:723-731.
28. Sugar A.M. Agent of mucormycosis and related species. Principles and Practices of Infectious Diseases 1995, 2311-2321. Churchill Livingstone. edn 4. G. Mandell, J. Bennett, R. Dolin (Eds.).
29. Waldorf A.R., Diamond R.D. Cerebral mucormycosis in diabetic mice after intrasinus challenge. Infect Immun 1984, 44:194-195.
30. Waldorf A.R., Ruderman N., Diamond R.D. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Investig 1984, 74:150-160.
31. Waldorf A.R., Halde C., Vedros N.A. Murine model of pulmonary mucormycosis in cortisone-treated mice. Sabouraudia 1982, 20:217-224.
32. Waldorf A.R. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol Ser 1989, 47:243-271.
33. Diamond R.D., Haudenschild C.C., Erickson N.F. Monocyte-mediated damage to Rhizopus oryzae hyphae in vitro. Infect Immun 1982, 38:292-297.
34. Chinn R.Y., Diamond R.D. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 1982, 38:1123-1129.
35. Oren H., Sahin B., Irken G., Ates H., Duman M., Yilmaz S., Turker M., Atabay B., Yaprak I. Neutrophil apoptosis in patients with beta-thalassemia major. Pediatr Hematol Oncol 2003, 20:237-243.
36. Cantinieaux B., Janssens A., Boelaert J.R., Lejeune M., Vermylen C., Kerrels V., Cornu G., Winand J., Fondu P. Ferritin-associated iron induces neutrophil dysfunction in hemosiderosis. J Lab Clin Med 1999, 133:353-361.
37. Guo D., Jaber B.L., Lee S., Perianayagam M.C., King A.J., Pereira B.J., Balakrishnan V.S. Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol 2002, 58:134-142.
38. Omara F.O., Blakley B.R. The effects of iron deficiency and iron overload on cell-mediated immunity in the mouse. Br J Nutr 1994, 72:899-909.
39. Gil-Lamaignere C., Simitsopoulou M., Roilides E., Maloukou A., Winn R.M., Walsh T.J. Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005, 191:1180-1187.
40. Ibrahim A.S., Gebermariam T., Fu Y., Lin L., Husseiny M.I., French S.W., Schwartz J., Skory C.D., Edwards J.E., Spellberg B.J. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007, 117:2649-2657.
41. Chamilos G., Lewis R.E., Hu J., Xiao L., Zal T., Gilliet M., Halder G., Kontoyiannis D.P. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci USA 2008, 105:9367-9372.
42. Kwon-Chung K.J., Bennett J.E. Mucormycosis. Medical Mycology 1992, 524-559. Lea, Febiger (Eds.).
43. Ibrahim A.S., Edwards J.E.J., Filler S.G. Zygomycosis. Clinical Mycology 2003, 241-251. Oxford University Press. W.E. Dismukes, P.G. Pappas, J.D. Sobel (Eds.).
44. Ben-Ami R., Luna M., Lewis R.E., Walsh T.J., Kontoyiannis D.P. A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. J Infect 2009, 59:134-138.
45. Ibrahim A.S., Spellberg B., Avanessian V., Fu Y., Edwards J.E. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun 2005, 73:778-783.
46. Liu M., Spellberg B., Phan Q.T., Fu Y., Lee A.S., Edwards J.E., Filler S.G., Ibrahim A.S. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 2010, 120:1914-1924.
47. Ibrahim A.S., Edwards J.E., Fu Y., Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006, 58:1070-1073.
48. Filler S.G., Swerdloff J.N., Hobbs C., Luckett P.M. Penetration and damage of endothelial cells by Candida albicans. Infect Immun 1995, 63:976-983.
49. Ibrahim A.S., Filler S.G., Alcouloumre M.S., Kozel T.R., Edwards J.E., Ghannoum M.A. Adherence to and damage of endothelial cells by Cryptococcus neoformans in vitro: role of the capsule. Infect Immun 1995, 63:4368-4374.
50. Isberg R.R., Leong J.M. Multiple beta 1 chain integrins are receptors for invasin, a protein that promotes bacterial penetration into mammalian cells. Cell 1990, 60:861-871.
51. Lee A.S. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 2007, 67:3496-3499.
52. Ni M., Lee A.S. ER chaperones in mammalian development and human diseases. FEBS Lett 2007, 581:3641-3651.
53. Li J., Lee A.S. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 2006, 6:45-54.
54. Wang M., Wey S., Zhang Y., Ye R., Lee A.S. Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders. Antioxid Redox Signal 2009, 11:2307-2316.
55. Chamilos G., Luna M., Lewis R.E., Bodey G.P., Chemaly R., Tarrand J.J., Safdar A., Raad I.I., Kontoyiannis D.P. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006, 91:986-989.
56. Pagano L., Offidani M., Fianchi L., Nosari A., Candoni A., Piccardi M., Corvatta L., D'Antonio D., Girmenia C., Martino P., et al. Mucormycosis in hematologic patients. Haematologica 2004, 89:207-214.
57. Eucker J., Sezer O., Graf B., Possinger K. Mucormycoses. Mycoses 2001, 44:253-260.